Advancing Parkinson’s disease research by organoid modeling and 3D imaging [WEBINAR]

For more information on complete workflows for cell analysis and 3D imaging of organoids, visit www.miltenyibi... Parkinson’s disease (PD) is a common neurodegenerative disorder characterized by the loss of dopaminergic neurons, which leads to nigrostriatal impairment. Although induced pluripotent stem cell (iPSC)-derived midbrain organoids can recapitulate human PD mechanisms more closely than animal models, they fail to reproduce nigrostriatal dopaminergic network dysregulation. Researchers recently developed assembloids with inducible aging to reproduce hallmarks of the striatal connectivity in PD. They used a powerful imaging technique called 3D light sheet microscopy to visualize the complex neural connections within midbrain-striatum assembloids without sectioning.
In this video, Professor Jens Christian Schwamborn (University of Luxembourg, Luxembourg) and Dr. Juan Eduardo Rodríguez-Gatica (University of Bonn, Germany) discuss using PSC-derived midbrain-striatal assembloids and a 3D light sheet microscopy workflow, highlighting its value not only to elucidate PD-related pathomechanisms, but also to accelerate the discovery of potential therapeutics.
Cerebral organoids (brain organoids) derived from human pluripotent stem cells (hPSCs), either embryonic or induced PSCs, have emerged as novel model systems that can be used to investigate human brain development and disorders. Miltenyi Biotec provides two complete workflows enabling the cellular analysis and 3D imaging of cerebral organoids.
Miltenyi Biotec is a global leader in innovating technologies and services for patient-specific cell and gene therapies, turning scientific discoveries into practical treatments for personalized medicine. Having pioneered a groundbreaking method of cell separation, Miltenyi Biotec continues to set industry standards today. With over 35 years of expertise, it supports customers in biomedical discoveries, translating them into clinical applications to enable access to new therapies for patients. Miltenyi Biotec focuses on providing integrated, advanced solutions to address complex challenges in the treatment of cancers, autoimmune diseases, and inherited disorders. Through its Miltenyi Bioindustry division, it provides expert guidance to therapy developers, helping them efficiently and cost-effectively navigate the path from process development to commercialization. Miltenyi Biotec is headquartered in Bergisch Gladbach and has a global team of 4,900 employees across 24 countries.